Internal link ProQR Announces First Quarter 2025 Operating and Financial Results mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth avril 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results mars 13, 2025 at 11:00 AM UTC
Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform décembre 22, 2022 at 11:15 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 novembre 14, 2022 at 09:30 PM UTC
Internal link ProQR Announces Third Quarter 2022 Operating and Financial Results novembre 09, 2022 at 12:00 PM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference novembre 03, 2022 at 11:00 AM UTC
Internal link ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs août 11, 2022 at 11:00 AM UTC
Internal link ProQR Announces Second Quarter 2022 Operating and Financial Results août 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium juin 28, 2022 at 11:00 AM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates juin 01, 2022 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022 mai 09, 2022 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2022 Operating and Financial Results mai 05, 2022 at 08:30 PM UTC
Internal link ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 avril 26, 2022 at 08:10 PM UTC
Internal link ProQR to Participate in the Kempen Life Sciences Conference avril 19, 2022 at 08:30 PM UTC
Internal link ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy avril 13, 2022 at 11:00 AM UTC
Internal link ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit avril 04, 2022 at 11:00 AM UTC
Internal link ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit mars 23, 2022 at 08:30 PM UTC
Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board mars 07, 2022 at 12:00 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results février 24, 2022 at 12:00 PM UTC
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 février 11, 2022 at 12:00 PM UTC